Amedisys (NASDAQ:AMED) Issues Earnings Results, Beats Expectations By $0.01 EPS

Amedisys (NASDAQ:AMED) announced its earnings results on Wednesday. The health services provider reported $1.03 EPS for the quarter, beating the consensus estimate of $1.02 by $0.01, Briefing.com reports. Amedisys had a positive return on equity of 13.00% and a negative net margin of 0.91%. The business had revenue of $571.41 million during the quarter, compared to the consensus estimate of $565.38 million. During the same period in the prior year, the business posted $1.00 earnings per share. Amedisys’s revenue was up 2.7% compared to the same quarter last year.

Amedisys Stock Up 0.5 %

AMED stock traded up $0.48 during mid-day trading on Friday, reaching $91.64. The company had a trading volume of 36,104 shares, compared to its average volume of 274,881. The company has a debt-to-equity ratio of 0.32, a current ratio of 1.05 and a quick ratio of 1.05. The stock has a 50 day simple moving average of $92.57 and a two-hundred day simple moving average of $93.35. Amedisys has a 52 week low of $73.10 and a 52 week high of $96.44. The company has a market capitalization of $2.99 billion, a price-to-earnings ratio of -142.84, a PEG ratio of 4.28 and a beta of 0.86.

Analyst Upgrades and Downgrades

A number of equities analysts have recently commented on AMED shares. Raymond James reissued a “market perform” rating on shares of Amedisys in a research report on Tuesday, March 26th. Royal Bank of Canada upped their target price on shares of Amedisys from $97.00 to $100.00 and gave the stock an “outperform” rating in a report on Monday, March 25th. StockNews.com initiated coverage on Amedisys in a research note on Monday, April 8th. They issued a “buy” rating for the company. Finally, Cantor Fitzgerald reaffirmed a “neutral” rating and set a $101.00 price objective on shares of Amedisys in a report on Thursday. Seven investment analysts have rated the stock with a hold rating and two have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of “Hold” and a consensus price target of $97.50.

About Amedisys

Amedisys, Inc, together with its subsidiaries, provides healthcare services in the United States. It operates through three segments: Home Health, Hospice, and High Acuity Care. The Home Health segment offers a range of services in the homes of individuals for the recovery of patients from surgery, chronic disability, or terminal illness, as well as prevents avoidable hospital readmissions through its skilled nurses; nursing services, rehabilitation therapists specialized in physical, speech, and occupational therapy; and social workers and aides for assisting its patients.